CMND
Clearmind Medicine Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.16
−31.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 52.6K | 49.4K | 51.1K | 57.4K | 119.6K |
| Gross Profit | (52.6K) | (49.4K) | (51.1K) | (57.4K) | (119.6K) |
| Operating Expenses | |||||
| R&D Expense | 2.4M | 2.0M | 1.4M | 1.5M | 4.4M |
| SG&A Expense | 5.6M | 3.6M | 4.3M | 4.7M | 4.5M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 8.0M | 5.6M | 5.7M | 6.2M | 8.9M |
| Cost and Expenses | 8.1M | 5.7M | 5.7M | 6.3M | 9.0M |
| Operating Income (EBIT) | (8.1M) | (5.7M) | (5.7M) | (6.3M) | (9.0M) |
| Non-Operating | |||||
| Interest Income | 163.9K | 132.9K | 271.2K | 59.1K | — |
| Interest Expense | 17.5K | 19.5K | 36.2K | — | 20.8K |
| Net Interest Income | 146.4K | 113.4K | 235.1K | 59.1K | (20.8K) |
| Other Non-Op Income/Expense | 209.2K | 1.9M | 868.2K | (2.3M) | (883.5K) |
| Non-Operating Income (excl Interest) | (695.7K) | (1.9M) | (904.4K) | 2.3M | 862.8K |
| EBT (Pre-Tax Income) | (7.9M) | (3.8M) | (4.9M) | (8.6M) | (9.9M) |
| Income Tax Expense | 17.7K | 70.4K | 378.0K | 17.3K | 43.0K |
| Bottom Line | |||||
| Net Income | (7.9M) | (3.9M) | (5.3M) | (8.6M) | (9.9M) |
| Earnings from Cont. Ops | (7.9M) | (3.9M) | (5.3M) | (8.6M) | (9.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.9M) | (3.9M) | (5.3M) | (8.6M) | (9.9M) |
| Per Share | |||||
| Basic EPS | ($11.56) | ($3.03) | ($6.78) | ($170.07) | ($916.44) |
| Diluted EPS | ($11.56) | ($3.03) | ($6.78) | ($170.07) | ($916.44) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 301964 | 1.3M | 775030 | 50620 | 10830 |
| Diluted Shares Outstanding | 301964 | 1.3M | 775030 | 50620 | 10830 |
| Profitability Metrics | |||||
| EBITDA | (7.3M) | (3.7M) | (4.8M) | (8.5M) | (9.7M) |
| D&A | 52.6K | 49.4K | 51.1K | 57.4K | 119.6K |
| EBIT | (7.4M) | (3.8M) | (4.8M) | (8.6M) | (9.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Apr 1, 2026